08:42 IST
NSE
Management Change
Gland Pharma Management Change
Gland Pharma Limited has appointed Mr. Deepak Sapra as the new Chief Executive Officer, effective from November 16, 2026.
Gland Pharma Ltd
Gland Pharma Ltd news stories on ALFA NewsRead the news →- Share price
- ₹3,150.60
- Market cap
- ₹51,988 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 46.1×Sector 47.3×
- Promoter holding
- 51.77%-0.06% QoQ
- FII holding
- 8.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Annual General Meeting 7Earnings Call 6Management Change 5Employee Stock Options 4Board Meeting Outcome 4Other Announcement 3Legal & Regulatory 3Business Update 3Financial Results 2Results Update 1Promoter Selling 1Product Launch 1New Order Win 1Merger & Restructuring 1Capital Structure Change 1Capacity Expansion 1Board Meeting Date 1Acquisition 1
Time
5 announcements with these filters
22:46 IST
NSE
Management Change
Gland Pharma Management Change
Gland Pharma shareholders approved the reappointment of Udo Jahannes Vetter and the appointment of William Robert Keller as Independent Directors for five-year terms.
16:12 IST
NSE
Management Change
Gland Pharma Management Change
Independent Director Mr. Satyanarayana Murthy Chavali resigned due to potential conflict of interest. His departure effective June 15, 2026, ensures governance standards.
18:32 IST
NSE
Management Change
Gland Pharma Management Change
Gland Pharma Limited reappointed Ms. Naina Lal Kidwai as Independent Director for five years starting May 2026. The reappointment ensures leadership stability and strong corporate governance.
- Execution
- 5 years
19:09 IST
NSE
Management Change
Gland Pharma Management Change
Gland Pharma Limited has re-appointed Ms. Naina Lal Kidwai as a Non-Executive Independent Director for a five-year term effective May 17, 2026. A Padma Shri recipient and former HSBC India Chairman, her extensive leadership experience across finance and industry continues to strengthen the company's board governance.
- Execution
- 5 years